VALRUBICIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VALRUBICIN (VALRUBICIN).
Anthracycline topoisomerase II inhibitor and DNA intercalator, causing DNA damage and cell death.
| Metabolism | Metabolized by hepatic esterases to N-trifluoroacetyladriamycin and adriamycin (doxorubicin); further metabolism by aldo-keto reductases. |
| Excretion | Primarily hepatic metabolism and biliary excretion; renal excretion accounts for <5% of unchanged drug. |
| Half-life | Terminal half-life is approximately 38 hours; clinically, it supports every-3-week dosing to avoid accumulation. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 4.7 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Intravesical administration: systemic bioavailability is low (<1%) due to limited absorption across the bladder wall; oral bioavailability is negligible due to extensive first-pass metabolism. |
| Onset of Action | Intravesical administration: onset within hours, with peak effect seen within 24-48 hours. |
| Duration of Action | The effect lasts approximately 7-10 days after intravesical instillation; repeated instillations are typically 3 weeks apart. |
Intravesical instillation: 800 mg (4 vials of 200 mg/5 mL) diluted in 25 mL of 0.9% Sodium Chloride Injection, instilled into the bladder once weekly for 6 weeks. Retain in bladder for 1-2 hours.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. Valrubicin is minimally absorbed systemically after intravesical administration. |
| Liver impairment | No dose adjustment required for hepatic impairment. Systemic absorption is negligible. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No specific dosing guidelines available. |
| Geriatric use | No specific geriatric dose adjustments; use same dosing as younger adults. Systemic exposure is minimal due to intravesical route. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VALRUBICIN (VALRUBICIN).
| Breastfeeding | It is unknown if valrubicin is excreted in human breast milk. Given its high molecular weight (approximately 723 g/mol) and poor oral bioavailability, transfer to milk is expected to be low. However, due to the potential for serious adverse reactions in the nursing infant, including bone marrow suppression and cardiotoxicity, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. The milk-to-plasma ratio (M/P) has not been determined. |
| Teratogenic Risk | Valrubicin is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on its mechanism of action as an anthracycline analog that inhibits DNA topoisomerase II, which is critical for cell division. Animal studies have demonstrated embryotoxicity and teratogenicity at doses lower than the human equivalent. Use during the first trimester is contraindicated due to high risk of major congenital malformations. During second and third trimesters, fetal exposure may cause growth restriction, preterm birth, and neonatal myelosuppression. The absolute risk is not quantified in humans due to lack of controlled studies. |
■ FDA Black Box Warning
Valrubicin is for intravesical use only and should not be administered by any other route. Severe bladder irritation, including hemorrhagic cystitis, may occur.
| Serious Effects |
Hypersensitivity to valrubicin or other anthracyclines, concurrent urinary tract infection, and small bladder capacity that prevents adequate instillation.
| Precautions | Monitor for bladder toxicity, including dysuria, urinary frequency, and hematuria. Use caution in patients with history of bladder cancer refractory to BCG. |
Loading safety data…
| Fetal Monitoring | For pregnant patients: baseline and serial complete blood counts to monitor for myelosuppression; liver and renal function tests; cardiac function assessment including echocardiogram due to potential cardiotoxicity (cumulative anthracycline effect). Fetal monitoring includes ultrasound for growth assessment and amniotic fluid volume every 4-6 weeks; non-stress testing or biophysical profile in the third trimester. Neonatal monitoring after delivery for signs of myelosuppression and cardiac function. |
| Fertility Effects | Valrubicin may impair fertility in both sexes due to its cytotoxic effects on rapidly dividing cells. In males, it can cause oligospermia or azoospermia, potentially irreversible. In females, it may induce ovarian failure, amenorrhea, and premature menopause, leading to reduced fertility. The effect is dose- and age-dependent. Pre-treatment fertility preservation counseling is recommended. |